RxDoctor Payments Data

Caitlyn Jennings, PA

Medical · Hyrum, UTNPI 1295187938

Payments from drug & device makers

$1,310in general payments, 2019–2025

Across 58 payments — averaging $22.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$253
  • Johnson & Johnson$197
  • Idorsia Pharmaceuticals US Inc$118
  • Janssen Scientific Affairs, LLC$115
  • Medtronic$97
  • Stimwave Technologies Incorporated$93
  • plus $437 from 16 others

What the payments were for

  • Consulting fees$1159%
  • Food & beverage$1,19591%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,310 in reported general payments places this provider in the 55th percentile of 263 medical providers in Utah.

See all medical providers in Utah

Medicare billing

Part B allowed, 2024
$11,020
Medicare patients
35
Services billed
241

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide25$26,029
OzempicSemaglutide25$23,908
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,023
Albuterol Sulfate HfaAlbuterol Sulfate26$761
Metformin Hcl20$420
Atorvastatin Calcium29$359
Quetiapine Fumarate13$342
Omeprazole15$279
Pantoprazole Sodium22$267
Escitalopram Oxalate17$218
Levothyroxine Sodium24$211
Lisinopril18$170
Bupropion XlBupropion Hcl11$159
Zolpidem Tartrate ErZolpidem Tartrate12$141
Rosuvastatin Calcium11$126

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$46$23,90825 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 263 medical providers in Utah.

Other medical in Hyrum

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →